Quantitative Determination of Epalrestat by RP-HPLC Method
 
More details
Hide details
1
Department of Pharmaceutical Chemistry, R. C. Patel Institute of Pharmaceutical Education and Research, Karwand Naka, Shirpur Dist. Dhule (MS) 425 405, India
CORRESPONDING AUTHOR
Atul A. Shirkhedkar   

Department of Pharmaceutical Chemistry, R. C. Patel Institute of Pharmaceutical Education and Research, Karwand Naka, Shirpur Dist. Dhule (MS) 425 405, India
Publish date: 2017-10-20
 
Eurasian J Anal Chem 2012;7(1):49–55
KEYWORDS
ABSTRACT
Epalrestat an aldose reductase inhibitor is used in the treatment of diabetic peripheral neuropathy. A simple, sensitive, precise and accurate RP-HPLC method for determination of epalrestat both as a bulk drug and in pharmaceutical formulation has been developed and validated as per the International Conference on Harmonization (ICH) guidelines. Chromatographic separation was achieved using Qualisil C8 column, detection at 294 nm and mixture of methanol: (0.01 mol L-1) potassium dihydrogen phosphate (75:25 v/v), pH adjusted to 4.5 with ortho-phosphoric acid as mobile phase. A typical retention time for eparlestat was 6.64 ± 0.02 min. Linearity was observed in concentration range of 2 – 12 μg.mL-1 with coefficient correlation (r2 = 0.999). The % RSD value for intra-day and inter-day precision was found to be in the range of 0.32 - 0.79 % and 0.12 -1.32 %. The mean % recovery was found to be in the range of 99.47 - 100.30 %. The low values of LOD (0.15 μg) and LOQ (0.46 μg) indicate high sensitivity of the method. The % RSD value for robustness and ruggedness studies was found to be less than 2 %. The amount of drug estimated was found to be in good agreement with label claim. The developed method can routinely be used for analysis of epalrestat in pharmaceutical formulations.
 
REFERENCES (10)
1.
Dong M W, (2006) Modern HPLC Practicing scientists, A John Wiley & Sons, New Jersey p.1-7.
 
2.
Iso K , Tada H , Kuboki K , Inokuchi T, (2001) Long-term effect of epalrestat, analdose reductase inhibitor, on the development of incipient diabetic nephropathy in Type 2 diabetic patients .Journal of Diabetes and Its Complications 15 : 241–244.
 
3.
Ito A, Nozawa R I, Ibuki C, (2009) Examination of Questionnaire Items regarding Diabetic Peripheral Neuropathy in Epalrestat-treated Patients and Their Usefulness in the Treatment of This Disorder Influence on Treatment Course, Journal of Pharmaceutical of Society Japan 129: 1239-1247.
 
4.
The Merck Index, (2006) Merck Research Laboratories division of White House Station 14th edition NJ: USA p.615.
 
5.
Hua T, (2000) to develop a reversed phase liquid chromatographic method for the determination of epalrestat in human plasma and study its pharmacokinetics, Chinese Pharmaceutical Journal.
 
6.
Saraf M N , Birajdar P G , Loya P , Mukherjee S A, (2007) Rapid and sensitive HPTLC method for determination of Epalrestat in human plasma , Journal Planar Chromatography 20: 3 203-207.
 
7.
Meiling Q, Peng W, Jianjun Y, (2004) Determination of Stereoisomers of Epalrestat by Liquid Chromatography, Journal of Beijing Institute Technology 13: 4.
 
8.
Q2 (A) R1. (2005) Validation of Analytical Procedures: Text and Methodology, International Conference on Harmonization, IFPMA Geneva, November.
 
9.
US FDA (1987) Guidelines for Submitting Samples and Analytical Data for Method Validation, Rockville MD, Center for Drug and Biologics Department of Health and Human services.
 
10.
Swartz M E, Krill I S, (2009) Analytical Method Development and Validation, Indian édition, Marcel Dekker, New York, p. 26, 27, 54,55.
 
eISSN:1306-3057